CA 19-9
|
WikiDoc Resources for CA 19-9 |
|
Articles |
|---|
|
Most recent articles on CA 19-9 |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CA 19-9 at Clinical Trials.gov Clinical Trials on CA 19-9 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CA 19-9
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating CA 19-9 Risk calculators and risk factors for CA 19-9
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CA 19-9 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. While it is not useful to diagnose particular forms of cancer, specifically pancreatic cancer, it may be useful to monitor the results of treatment and to determine whether the disease may be recurring.[1] Other causes for elevated CA19-9 levels include Mirizzi's syndrome and other hepatobiliary diseases.[2] In patients that have the Lewis antigen blood type, CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of fucosyltransferase that is needed to produce CA19-9.
References
- ↑ Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006). "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer". J. Clin. Oncol. 24 (33): 5313–27. PMID 17060676.
- ↑ Robertson A, Davidson B (2007). "Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9". European journal of gastroenterology & hepatology. 19 (2): 167–9. PMID 17273004.